“`html
National Research Corporation (NRC Health) reported a 12.3% increase in shares following its earnings announcement for the quarter ended September 30, 2025, outperforming the S&P 500’s 1.5% growth. NRC’s total revenues for the quarter were $34.6 million, down from $35.8 million year-over-year, with adjusted net income at 23 cents per share, compared to 25 cents a year ago.
The company’s Total Recurring Contract Value (TRCV) rose by 8% to $141.7 million, marking the fourth consecutive quarter of growth. Cash flow from operations improved by 46% to $13.8 million, representing 40% of total revenues. NRC also repurchased 618,264 shares at an average price of $14.99, returning a total of $28.1 million to shareholders through dividends and buybacks in 2025.
For the quarter, adjusted EBITDA increased by 11% to $10.9 million, with a margin improvement to 31.4%. In light of its cash flow performance, NRC raised its quarterly dividend by 33% to 16 cents per share, payable in January 2026.
“`
